Free tool
FAERS Monitor: Akeega
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216793 or its brand name (Akeega, Abiraterone Acetate, Niraparib Tosylate). Reports on generic versions are filed under their own applications.
Reports
62
Serious
45
73% of reports
Hospitalization
19
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6
- constipation4
- decreased appetite4
- fatigue4
- nausea4
- product ineffective for unapproved use4
- prostatic specific antigen increased4
- abdominal pain upper3
- blood pressure increased3
- death3
- dizziness3
- drug ineffective3
- malaise3
- pancytopenia3
- adverse event2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 25 |
| 2025 | 16 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,097 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product ineffective for unapproved useSignal | 4 | 511.0 | 197.9 | 1,556 |
| prostatic specific antigen increasedSignal | 4 | 98.5 | 38.2 | 295 |
| pancytopeniaSignal | 3 | 18.2 | 6.0 | 33 |
| adverse event | 2 | 7.4 | 1.9 | 6 |
| blood pressure increasedSignal | 3 | 6.7 | 2.2 | 9 |
| constipationSignal | 4 | 6.2 | 2.4 | 13 |
| decreased appetiteSignal | 4 | 5.8 | 2.3 | 12 |
| abdominal pain upperSignal | 3 | 4.9 | 1.6 | 6 |
| off label use | 6 | 2.3 | 1.1 | 3 |
| malaise | 3 | 2.3 | 0.8 | 1 |
| dizziness | 3 | 2.0 | 0.7 | 1 |
| fatigue | 4 | 1.7 | 0.7 | 1 |
| nausea | 4 | 1.7 | 0.7 | 1 |
| death | 3 | 1.2 | 0.4 | 0 |
| drug ineffective | 3 | 0.8 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.